EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis

Kieren J Mather iD, Andrea Mari, Govinda Weerakkody, Tim Heise iD, J Hans DeVries iD, Shweta Urva iD, Tamer Coskun iD, Zvonko Milicevic iD, Axel Haupt iD, Melissa K Thomas

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16159 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kieren J Mather und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Type 2, Weight Loss, Glucagon-Like Peptides. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To explore the relationship between weight loss and insulin sensitivity in response to tirzepatide or semaglutide. Materials and Methods We conducted a post hoc exploratory analysis of a 28‐week, double‐blind, randomized trial in people with type 2 diabetes treated with metformin, randomized to tirzepatide 15 mg, semaglutide 1 mg or placebo. We evaluated the relationship between change in body weight and change in insulin sensitivity determined from hyperinsulinemic euglycemic clamp ( M value), or from mixed‐meal tolerance testing (Matsuda index).

Results

Tirzepatide was associated with a greater improvement than semaglutide in insulin sensitivity assessed using hyperinsulinemic euglycemic clamps ( p < 0.001). With tirzepatide, improvements in insulin sensitivity were associated with percent change in weight ( R = −0.656, p < 0.0001). With semaglutide, change in insulin sensitivity was less strongly correlated with percent change in weight ( R = −0.268, p = 0.0820; p = 0.0242 vs. tirzepatide). In regression analyses, the slope of the relationship between change in M value and change in weight was statistically different between semaglutide and tirzepatide ( p = 0.0461). These relationships were also assessed using the Matsuda index as the metric of insulin sensitivity, and using change in fat mass as the determinant of change in insulin sensitivity.

Conclusions

Improvement in insulin sensitivity was proportional to weight and fat loss, with greater strength of association with tirzepatide. In regression analysis, tirzepatide was associated with greater improvement in insulin sensitivity per unit weight loss than semaglutide. The greater improvement in insulin sensitivity following treatment with tirzepatide was not simply attributable to greater weight or fat loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceDiabetes Mellitus, Type 2Weight LossGlucagon-Like PeptidesHypoglycemic AgentsHumansMaleFemaleMiddle AgedDouble-Blind MethodTirzepatideGlucose Clamp TechniqueMetforminBlood GlucoseAgedTreatment OutcomeGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GIPGLP‐1insulin sensitivitytirzepatideweight loss

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsTirzepatideMetforminBlood GlucoseGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Institute of Neuroscience, National Research Council, Padova, Italy.
  • Profil, Neuss, Germany.

ORCID-Profile: Kieren J Mather, Tim Heise, J Hans DeVries, Shweta Urva, Tamer Coskun, Zvonko Milicevic, Axel Haupt

Förderung

  • Eli Lilly and Company

Zitieren

APA

Mather, K. J., Mari, A., Weerakkody, G., Heise, T., DeVries, J. H., Urva, S., Coskun, T., Milicevic, Z., Haupt, A., & Thomas, M. K. (2025). Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16159

Vancouver

Mather KJ, Mari A, Weerakkody G, Heise T, DeVries JH, Urva S, et al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16159

BibTeX
@article{Mather2025,
  author = {Mather, Kieren J and Mari, Andrea and Weerakkody, Govinda and Heise, Tim and DeVries, J Hans and Urva, Shweta and Coskun, Tamer and Milicevic, Zvonko and Haupt, Axel and Thomas, Melissa K},
  title = {Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16159}
}
Kostenlos starten →